Repatha® is covered by Manitoba Drug Benefits and Interchangeability Formulary (Exception Drug Status) for HeFH
and by the majority of private drug plans for HeFH and ASCVD

MANITOBA FORMULARY REIMBURSEMENT CRITERIA

Diagnosis: Definite or probable diagnosis of HeFH using the Simon Broome or Dutch Lipid Network criteria or genetic testing.

Treatment: Patient must be on a high-dose statin (i.e., atorvastatin 80 mg or rosuvastatin 40 mg) in combination with ezetimibe for at least a total of 3 months.

LDL-C target: Patient is unable to reach low-density lipoprotein cholesterol (LDL-C) target (i.e., LDL-C <2.0 mmol/L for secondary prevention) or at least a 50% reduction in LDL-C from untreated baseline despite confirmed adherence to treatment

OR

For patients unable to tolerate high-dose statin:

Inability to tolerate at least two statins with at least one started at the lowest starting daily dose	**AND**	For each statin (two statins in total), dose reduction is attempted for intolerable symptom (myopathy) or biomarker abnormality (creatine kinase [CK] >5 times the upper limit of normal [ULN]) resolution rather than discontinuation of statin altogether	**AND**	For each statin (two statins in total), intolerable symptoms (myopathy) or abnormal biomarkers (CK >5xULN) changes are reversible upon statin discontinuation but reproducible by rechallenge of statins where clinically appropriate	**AND one of either:**	Other known determinants of intolerable symptoms or abnormal biomarkers have been ruled out **OR** Patient developed confirmed and documented rhabdomyolysis **OR** Patient is statin-contraindicated, i.e., active liver disease, unexplained persistent elevations of serum transaminases exceeding 3xULN	**AND**	Confirmed adherence to ezetimibe for at least a total of 3 months

ASCVD=atherosclerotic cardiovascular disease; HeFH=heterozygous familial hypercholesterolemia

Reference: Manitoba Drug Benefits and Interchangeability Formulary, Bulletin #106, March 2, 2020. www.gov.mb.ca/health/mdbif/docs/bulletins/bulletin106.pdf Accessed February 19, 2020.

Pr Repatha® (evolocumab)